A phase 1–2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer

Autor:	Lisle Nabell, M. B. Meyer, Mary Varterasian, Smitha S. Krishnamurthi, S. S. Menon, G. Croghan, S. S. Sadis, J. Leopold, J. R. Rinehart, Patricia Lorusso
Rok vydání:	2005
Předmět:	MAPK/ERK pathway Cancer Research Kinase business.industry MEK inhibitor environment and public health Advanced cancer Clinical study Oncology Cancer research Phosphorylation Medicine In patient business
Zdroj:	Journal of Clinical Oncology. 23:3011-3011
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2005.23.16_suppl.3011
Popis:	3011 Background: Oral PD 0325901 is a potent inhibitor of the dual-specificity kinases, MEK1/2 (MAPK/ERK/Kinase), thereby preventing phosphorylation and subsequent activation of mitogen-activated p...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8dd9147d954c42c5686a8b1300390883 https://doi.org/10.1200/jco.2005.23.16_suppl.3011 Zobrazit plný text záznamu